Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dietary Supplement Content Analyses On FTC Agenda For 2000

This article was originally published in The Tan Sheet

Executive Summary

The integrity of dietary supplement nutrient content claims may come under increased scrutiny by the Federal Trade Commission in the coming months.

You may also be interested in...



Dietary Supplement Implied Disease Claims Still Not Suitable - FDA

FDA affirms its position that "structure/function claims should not imply disease treatment or prevention" in the agency's final rule on dietary supplement claims criteria published in the Jan. 6 Federal Register.

Hot Flashes, PMS Structure/Function Claims Allowed Under Final Rule

FDA will permit dietary supplement makers to make structure/function claims for "common, mild symptoms associated with normal life stages or processes." Examples of allowable claims include hot flashes associated with menopause and mild mood changes, cramps and edema related to the menstrual cycle.

FTC Criteria For Structure/Function Claim Ad Evaluation Sought By Marketers

The Federal Trade Commission either should issue advisory opinions concerning dietary supplement structure/function claim advertising or define the criteria it uses in deciding whether such ads satisfy the "competent and reliable scientific evidence" standard, four supplement marketers say in a petition for rulemaking filed with FTC Dec. 21.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel